Biocon Biologics has one of the deepest portfolios of biosimilars in the industry, spanning across insulin, monoclonal antibodies and conjugated recombinant proteins. Our long-term investments in R&D have yielded several molecules in diabetes, oncology, immunology, ophthalmology and bone health of which eight have been already commercialized in markets globally.
The biosimilars that we are developing can potentially address a USD 70 billion global market opportunity by FY27.
A robust portfolio with both depth and breadth across therapeutic areas mean Biocon Biologics has new product launches planned almost every year through 2030.